We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva (TEVA) Misses on Q4 Earnings, Beats Sales, Shares Down
Read MoreHide Full Article
Israel-based Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. The company’s branded products include Copaxone (multiple sclerosis), Azilect (Parkinson’s disease), Austedo (chorea associated with Huntington’s disease and tardive dyskinesia) and respiratory products like ProAir and Qvar.
Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Nonetheless, Teva is progressing well on its strategic/restructuring initiatives to revive growth.
Teva’s earnings surpassed expectations in all the last four quarters, resulting in an average positive surprise of 23.28%.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Miss: Teva’s fourth-quarter earnings came in at 53 cents per share which missed consensus estimate of 56 cents.
Revenues Beat: Teva posted revenues of $4.56 billion, which marginally beat consensus estimates of $4.54 billion. Sales declined 16% (down 14% in constant currency terms) year over year.
Key Statistics: North America segment sales were $2.23 billion, down 17% year over year due to pricing erosion in U.S. generics market, lower sales of Copaxone as well as ProAir and QVAR, and loss of sales from the divested Women’s Health business. Growth in Austedo sales partially offset the decline in sales. In the United States, revenues declined 17% to $2.1 billion.
Lead branded product, Copaxone, posted sales of $356 million in North America, down 44% year over year due to generic competition in the United States. Sales of generic products declined 10% to $1.1 billion. However, sales of Austedo increased from $17 million in year-ago period to $68 million.
The Europe segment recorded revenues of $1.2 billion, down 17% (down 14% in constant currency terms) year over year. In the International Markets segments, sales declined 13% in constant currency terms.
2019 Outlook Weak: Teva provided its guidance for sales and earnings in 2019. The company expects revenues to be in the range of $17 - $17.4 billion. Meanwhile, the earnings guidance lie in a band of $2.20-2.50 per share. However, earnings and sales outlook were lower than the Zacks consensus estimates.
Share Price Impact: Shares were down more than 12.1% in pre-market trading.
Check back later for our full write up on this TEVA earnings report later!
Teva Pharmaceutical Industries Ltd. Price and EPS Surprise
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Image: Bigstock
Teva (TEVA) Misses on Q4 Earnings, Beats Sales, Shares Down
Israel-based Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. The company’s branded products include Copaxone (multiple sclerosis), Azilect (Parkinson’s disease), Austedo (chorea associated with Huntington’s disease and tardive dyskinesia) and respiratory products like ProAir and Qvar.
Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Nonetheless, Teva is progressing well on its strategic/restructuring initiatives to revive growth.
Teva’s earnings surpassed expectations in all the last four quarters, resulting in an average positive surprise of 23.28%.
Currently, TEVA has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Miss: Teva’s fourth-quarter earnings came in at 53 cents per share which missed consensus estimate of 56 cents.
Revenues Beat: Teva posted revenues of $4.56 billion, which marginally beat consensus estimates of $4.54 billion. Sales declined 16% (down 14% in constant currency terms) year over year.
Key Statistics: North America segment sales were $2.23 billion, down 17% year over year due to pricing erosion in U.S. generics market, lower sales of Copaxone as well as ProAir and QVAR, and loss of sales from the divested Women’s Health business. Growth in Austedo sales partially offset the decline in sales. In the United States, revenues declined 17% to $2.1 billion.
Lead branded product, Copaxone, posted sales of $356 million in North America, down 44% year over year due to generic competition in the United States. Sales of generic products declined 10% to $1.1 billion. However, sales of Austedo increased from $17 million in year-ago period to $68 million.
The Europe segment recorded revenues of $1.2 billion, down 17% (down 14% in constant currency terms) year over year. In the International Markets segments, sales declined 13% in constant currency terms.
2019 Outlook Weak: Teva provided its guidance for sales and earnings in 2019. The company expects revenues to be in the range of $17 - $17.4 billion. Meanwhile, the earnings guidance lie in a band of $2.20-2.50 per share. However, earnings and sales outlook were lower than the Zacks consensus estimates.
Share Price Impact: Shares were down more than 12.1% in pre-market trading.
Check back later for our full write up on this TEVA earnings report later!
Teva Pharmaceutical Industries Ltd. Price and EPS Surprise
Teva Pharmaceutical Industries Ltd. Price and EPS Surprise | Teva Pharmaceutical Industries Ltd. Quote
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>